
Gilead Sciences/LinkedIn
Jun 20, 2025, 11:30
Gilead Sciences – Daniel O’Day Discusses the Approval of a New HIV Prevention Drug and Its Impact in an Open Letter
Gilead Sciences posted on LinkedIn:
“Gilead News: In an open letter, Chairman and Chief Executive Officer Daniel O’Day discusses our just-approved HIV prevention medication and its role in our fight to help end the epidemic.”
More posts featuring Gilead Sciences.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 20, 2025, 10:48